Dana-Farber Cancer Institute | Strategic Alliance Partners

February 28, 2023

Paul L. Nguyen, MD, discusses primary findings from the phase 2 FORMULA-509 trial in prostate cancer.

February 25, 2023

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

February 20, 2023

Bradley McGregor, MD, discusses the investigation of cabozantinib plus atezolizumab in patients with non–clear cell renal cell carcinoma.

February 20, 2023

Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.

February 16, 2023

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

February 16, 2023

ADI-001, a first-in-class, allogeneic gamma delta1 CAR T-cell therapy, elicited responses and demonstrated a favorable safety profile in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

February 16, 2023

Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration for the treatment of metastatic HR+, HER2- breast cancer.

February 14, 2023

Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.

February 14, 2023

Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.

February 13, 2023

Massimo Cristofanilli, MD, and Sara Tolaney, MD, MPH, offer closing remarks on the HR+ breast cancer treatment landscape, offer advice for community oncologists, and look to the future.

February 10, 2023

In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted in substantially better responses than standard treatments.

February 09, 2023

Praful K. Ravi, MB, BChir, MRCP, discusses ongoing and future clinical trials investigating the use of prostate-specific membrane antigen-targeted therapies in metastatic castration-resistant prostate cancer.

February 08, 2023

Atish D. Choudhury, MD, PhD, discusses key biomarkers that may assist in the prediction of PARP inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC).

February 07, 2023

Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.

February 06, 2023

A detailed look at treatment options for patients with metastatic HR+ breast cancer who have progressed on CDK4/6 inhibitors.

February 06, 2023

Experts in oncology consider when surgery is appropriate for patients with breast cancer.

February 02, 2023

Stephanie A. Berg, DO, highlights ongoing urothelial cancer clinical trials; the role of single-agent immunotherapy and combinations in this disease; and the importance of future research that prioritizes and guides individualized patient care.

February 01, 2023

Atish D. Choudhury, MD, PhD, discussed the significance of these trials within the metastatic castration-resistant prostate cancer treatment landscape, highlighted investigative PARP inhibitor combinations, and emphasized the need for further research in this area to determine which patients are most likely to benefit from certain therapies based on their molecular profiles.

February 01, 2023

A three-drug combination that sent chronic lymphocytic leukemia into deep remissions in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase 2 clinical trial led by Dana-Farber Cancer Institute investigators indicates.

January 30, 2023

In a new study, scientists at Dana-Farber Cancer Institute identify, for the first time, inherited genetic variations that place patients at high risk for these complications.